Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 16/20 | 0.66 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.57 |
| ▸ | MIF | P14174 | 1/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14289688 | 0.90 | ESR1 (0.60) | ESR1ESR2MIFMMP3BCL2L1 | |
| SCHEMBL3652303 | 0.88 | ESR1 (0.79) | ESR1ESR2 | |
| SCHEMBL5109423 | 0.84 | ESR1 (0.66) | ESR1ESR2MIF | |
| SCHEMBL5109426 | 0.84 | ESR1 (0.66) | ESR1ESR2MIF | |
| SCHEMBL23195962 | 0.81 | ESR1 (0.65) | ESR1ESR2 | |
| SCHEMBL23195741 | 0.80 | ESR1 (0.78) | ESR1ESR2 | |
| SCHEMBL2824657 | 0.79 | CES1 (0.45) | ESR1ESR2 | |
| SCHEMBL5110186 | 0.78 | ESR1 (0.57) | ESR1ESR2MIF | |
| SCHEMBL5124981 | 0.78 | FFAR1 (0.54) | ESR1 | |
| SCHEMBL5110464 | 0.78 | ESR1 (0.57) | ESR1ESR2MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323587-B2 | Selective estrogen receptor modulators | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323587-B2 | Selective estrogen receptor modulators | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323587-B2 | Selective estrogen receptor modulators | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-29 | — | — | US | disclosed |
| US-7145015-B2 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain that latter as well as their use for the production of pharmaceutical agents | SCHERING AG (DE) | 2006-12-05 | — | — | US | disclosed |
| US-7045540-B2 | Selective estrogen receptor modulators | BRISTOL MEYERS SQUIBB COMPANY (US) | 2006-05-16 | — | — | US | disclosed |
| US-20050267183-A1 | Selective estrogen receptor modulators | KALTENBACH ROBERT F | 2005-12-01 | — | — | US | disclosed |
| US-20050245602-A1 | Selective estrogen receptor modulators | KALTENBACH ROBERT F | 2005-11-03 | — | — | US | disclosed |
| US-20050182081-A1 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-08-18 | — | — | US | disclosed |
| US-6927224-B2 | Selective estrogen receptor modulators | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-08-09 | — | — | US | disclosed |
| US-6878750-B2 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents | SCHERING AG (DE) | 2005-04-12 | — | — | US | disclosed |
| EP-1417169-A2 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Bristol-Myers Squibb Pharma Company (US) | 2004-05-12 | — | — | EP | disclosed |
| EP-1098874-B1 | BENZOCYCLOHEPTENES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS, AND THEIR USE FOR PRODUCING MEDICAMENTS | SCHERING AG (DE) | 2003-06-18 | — | — | EP | disclosed |
| US-20030105148-A1 | Selective estrogen receptor modulators | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-06-05 | — | — | US | disclosed |
| US-20030050324-A1 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents | SCHERING AG (DE) | 2003-03-13 | — | — | US | disclosed |
| WO-2003016270-A2 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| US-6495607-B2 | 8,9-DIHYDRO-7H-BENZOCYCLOHEPTENE DERIVATIVES ARE USEFUL FOR PHOPHYLAXIS AND THERAPY OF OSTEOPOROSIS(HAVE SELECTIVE ESTROGENIC ACTIVITY ON BONES) | SCHERING AG (DE) | 2002-12-17 | — | — | US | disclosed |
| US-20020068765-A1 | BENZOCYCLOHEPTENES, PROCESS FOR THEIR PRODUCTION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THE LATTER AS WELL AS THEIR USE FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2002-06-06 | — | — | US | disclosed |
| EP-1098874-A1 | BENZOCYCLOHEPTENES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS, AND THEIR USE FOR PRODUCING MEDICAMENTS | Schering Aktiengesellschaft (DE) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000003979-A1 | BENZOCYCLOHEPTENES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS, AND THEIR USE FOR PRODUCING MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245602-A1 | Selective estrogen receptor modulators | ESR1, ESR2, GPER1 | ESR1 1/4885ESR2 2/4885MIF 238/4885 |
| US-20020068765-A1 | BENZOCYCLOHEPTENES, PROCESS FOR THEIR PRODUCTION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THE LATTER AS WELL AS THEIR USE FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS | CYP19A1, ESRRA, SULT2A1 | ESR1 36/4885ESR2 5/4885MIF 4364/4885 |
| US-20030105148-A1 | Selective estrogen receptor modulators | ESR1, GPER1, PTGIR | ESR1 1/4885ESR2 8/4885MIF 2090/4885 |
| US-20050182081-A1 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents | CYP19A1, ESR2, ESRRA | ESR1 8/4885ESR2 2/4885MIF 4448/4885 |
| US-20030050324-A1 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents | CYP19A1, ESRRA, SULT2A1 | ESR1 36/4885ESR2 5/4885MIF 4364/4885 |
| US-20050267183-A1 | Selective estrogen receptor modulators | ESR2, ESR1, GPER1 | ESR1 2/4885ESR2 1/4885MIF 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.